Universal health care, genomic medicine and Thailand: Investing in today and tomorrow

Nature Reviews Genetics

Volumn 9, Issue SUPPL.1, 2008, Pages

  Séguin, Béatrice ^a   Hardy, Billie Jo ^a   Singer, Peter A ^a,b   Daar, Abdallah S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MaRS Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; ETHNICITY; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; HUMAN GENOME PROJECT; MEDICAL EDUCATION; OUTCOME ASSESSMENT; PHARMACOGENOMICS; POPULATION GENETIC STRUCTURE; PRIORITY JOURNAL; RACE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND;

DELIVERY OF HEALTH CARE; DIFFUSION OF INNOVATION; ETHNIC GROUPS; GENOMICS; HEALTH SERVICES ACCESSIBILITY; HUMANS; LEADERSHIP; POLITICS; POLYMORPHISM, SINGLE NUCLEOTIDE; THAILAND; UNIVERSAL COVERAGE;

EID: 52149117603     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg2443     Document Type: Review

References (39)

1. Marsh, S., Van Booven, D. J. & McLeod, H. L. Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics 7, 625-631 (2006).
2. Stone, R. Mongkol na Songkhla interview. Thai health minister defends controversial drug-patent policy. Science 316, 1408 (2007).
3. Séguin, B., Hardy, B., Singer, P. A. & Daar, A. S. Genomic medicine and developing countries: creating a room of their own. Nature Rev. Genet. 9, 487-493 (2008).
4. Séguin, B., Hardy, B., Singer, P. A. & Daar, A. S. Human genomic variation initiatives in emerging economies and developing countries Nature Rev. Genet. 9 (Suppl), S3-S4 (2008).
5. Hughes, C. A. et al. Abacavir hypersensitivity reaction: an update. Ann. Pharmacother. 42, 387-396 (2008).
6. Hughes, A. R. et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5, 203-211 (2004).
7. Hughes, A. R. et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J. 11 March 2008 (doi: 10.1038/tpj.2008.3).
8. Sadiq, S. T. & Pakianathan, M. Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK. Sex. Transm. Infect. 83, 181-182 (2007).
9. Watson, M. E., Pimenta, J. M., Spreen, W. R. & Hernandez, J. E. HLA-B*5701 and abacavir hypersensitivity. Pharmacogenetics 14, 783-784 (2004); author reply 14, 784 (2004).
10. Rauch, A. et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis. 43, 99-102 (2006).
11. Zucman, D., Truchis, P., Majerholc, C., Stegman, S. & Caillat-Zucman, S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J. Acquir. Immune Defic. Syndr. 45, 1-3 (2007).
12. International Labour Office. A Technical Note to the Government: Financing Universal Health Care in Thailand. [online], 〈http://www.ilo.org/ public/english/protection/secsoc/downloads/publ/995sp1.pdf〉 (2004).
13. Phanuphak, N. et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med. 8, 357-366 (2007).
14. The Ministry of Public Health and The National Health Security Office Thailand. Facts and evidences on the 10 burning issues related to the government use of patents on three patented essential drugs in Thailand. [online], 〈http://www.moph.go.th/hot/White%20Paper%20CL-EN.pdf〉 (2007).
15. Kiertiburanakul, S., Khongnorasat, S., Rattanasiri, S. & Sungkanuparph, S. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. J. Med. Assoc. Thai. 90, 237-243 (2007).
16. Stone, R. Indian Ocean tsunami. In the wake: looking for keys to posttraumatic stress. Science 310, 1605 (2005).
17. Séguin, B., Hardy, B., Singer, P. A. & Daar, A. S. Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN). Nature Rev. Genet. 9 (Suppl), S5-S9 (2008).
18. Becerril, A. Aprueba el Senado sanciones a quienes trasladen tejido humano fuera de México. La Journada [online], 〈http://www. jornada.unam.mx/2008/03/28/index.php?section=sociedad&article= 046n1soc〉 (2008).
19. [No authors listed]. Friendly cooperation agreement signed by Tsinghua Science Park and Thailand Science Park. Tsinghua Science Park [online], 〈http://www.thsp.com.cn/english/news/20070926Thailand/news.htm〉 (2007).
20. Jayaraman, K. S. Database targets Parsi genes. Nature 446, 475 (2007).
21. Chantratita, W. in Maximize the Effectiveness of HIV-1 Treatment by Using Molecular Techniques, Bioinformatics, and Pharmacogenomics. 275 (Graphic Hut Co., Ltd, Bangkok, 2008).
22. Secretary's Advisory Committee on Genetics, Health, and Society. Realizing the potential of pharmacogenomics: opportunities and challenges. [online], 〈http://www4.od.nih.gov/oba/SACGHS/reports/SACGHS_PGx_Report. pdf〉 (2008).
23. Intarakumnerd, P. & Chaminade, C. Strategy versus practice in innovation systems policy: the case of Thailand. Asian Journal of Technology Innovation 15, 197-213 (2007).
24. Ford, N., Wilson, D., Costa Chaves, G., Lotrowska, M. & Kijtiwatchakul, K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS 21 (Suppl 4), S21-S29 (2007).
25. Seim, L. Thailand: government issues compulsory licences for HIV/AIDS drugs. HIV AIDS Policy. Law. Rev. 12, 28-29 (2007).
26. Steinbrook, R. Thailand and the compulsory licensing of efavirenz. N. Engl. J. Med. 356, 544-546 (2007).
27. Supakankunti, S. et al. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand. Bull. World Health Organ. 79, 461-470 (2001).
28. Thorsteinsdottir, H., Quach, U., Daar, A. S. & Singer, P. A. Conclusions: promoting biotechnology innovation in developing countries. Nature Biotechnol. 22 (Suppl), DC48-DC52 (2004).
29. Frew, S. E. et al. India's health biotech sector at a crossroads. Nature Biotechnol. 25, 403-417 (2007).
30. Bowser, R. Race as a proxy for drug response: the dangers and challenges of ethnic drugs. DePaul Law Rev. 53, 1111-1126 (2004).
31. Burchard, E. G. et al. The importance of race and ethnic background in biomedical research and clinical practice. N. Engl. J. Med. 348, 1170-1175 (2003).
32. Lee, S. S. The ethical implications of stratifying by race in pharmacogenomics. Clin. Pharmacol. Ther. 81, 122-125 (2007).
33. Tang, H. Confronting ethnicity-specific disease risk. Nature Genet. 38, 13-15 (2006).
34. Risch, N., Burchard, E., Ziv, E. & Tang, H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol. 3, comment2007.1-200712 (2002).
35. Séguin, B., Hardy, B., Singer, P. A. & Daar, A. S. Bidil: recontextualizing the race debate. Pharmacogenomics J. 8, 169-173 (2008).
36. Indian Genome Variation Consortium. Genetic landscape of the people of India: a canvas for disease gene exploration. J. Genet. 87, 3-20 (2008).
37. Mudur, G. S. Stamp on Tagore's India Genetic map blurs lines. The Telegraph (Calcutta, India) [online], 〈http://www.telegraphindia.com/ 1080425/jsp/frontpage/story_9186161.jsp〉 (2008).
38. Boutayeb, A. The double burden of communicable and non-communicable diseases in developing countries. Trans. R. Soc. Trop. Med. Hyg. 100, 191-199 (2006).
39. Daar, A. S. et al. Grand challenges in chronic noncommunicable diseases. Nature 450, 494-496 (2007).